IDH2 and neoplasm: Wang et al. from Agios Pharmaceuticals, developed a small molecule, AGI-6780 (Compound 4), that potently and selectively inhibited the tumor-associated mutant IDH2 R140Q (IC50 = 170 nM) [116].